SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:485334f5-1241-4527-9e46-71c7d9ef4940"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:485334f5-1241-4527-9e46-71c7d9ef4940" > New strategies for ...

  • Olivier, CecilleEuropean Medicines Agency (EMA) (författare)

New strategies for the conduct of clinical trials in paediatric Pulmonary Arterial Hypertension (PAH): Outcome of a multi-stakeholder meeting with patients, academia, industry and regulators held at EMA on Monday 12th June 2017

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:485334f5-1241-4527-9e46-71c7d9ef4940
  • https://lup.lub.lu.se/record/485334f5-1241-4527-9e46-71c7d9ef4940URI
  • https://doi.org/10.1161/JAHA.118.011306DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Aims: Drug development for paediatric pulmonary arterial hypertension (PAH) ispressingly needed. Experts from the US Food and Drug Administration, EuropeanMedicines Agency, Health Canada, key opinion leaders, academia, patients, and industry representatives held a workshop on 12th June 2017 dedicated to addressing challenges and unmet needs. This report summarises the approaches proposed during the meeting to address key issues in extrapolation, trial design, and study endpoints in pediatric drug development.Methods and Results: A pre-workshop stakeholder survey was conducted and showed that most respondents believe the pathophysiology of heritable PAH and some forms of idiopathic PAH is thought to be sufficiently similar in adult and paediatric patients, although the clinical manifestations may differ. In this situation, placebo-controlled trials might not be required to confirm clinical benefit in paediatrics. The study endpoints used to support drug approvals in adults were reviewed to determine if these existing study endpoints can be applied in paediatric PAH efficacy trials. It showed that non-invasive study endpoints, such as the time to clinical worsening, WHO functionalclass, and 6-Minute-Walk-Test could be applicable in paediatric PAH trials, although each presents some limitations in paediatrics.Conclusion: Extrapolation of efficacy from informative adult studies may be appropriate in some forms of PAH. Initial dose-finding studies and exposure-response modelling are warranted in paediatric PAH, followed by an efficacy and safety study to explore the response to treatment and exposure-response relationship. A novel, non-invasive, developmentally-appropriate, and reliable study endpoint needs to be developed.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Sun, HaihaoUnited States Food and Drug Administration (författare)
  • Amchin, WayneUnited States Food and Drug Administration (författare)
  • Beghetti, MauriceGeneva University Hospital (författare)
  • Berger, RolfUniversity of Groningen (författare)
  • Breitenstein, StefanieBayer Pharma AG (författare)
  • Garnett, ChristineUnited States Food and Drug Administration (författare)
  • Gullberg, NinnaEuropean Medicines Agency (EMA) (författare)
  • Hassel, PatrikPH Sweden (författare)
  • Ivy, DumbarUniversity of Colorado School of Medicine (författare)
  • Kawut, StevenUniversity of Pennsylvania (författare)
  • Klein, AgnesPublic Health Agency of Canada (författare)
  • Lesage, CatherineActelion Pharmaceuticals Ltd. (författare)
  • Migdal, MarekChildren’s Memorial Health Institute (författare)
  • Nije, BarbaraPublic Health Agency of Canada (författare)
  • Odermarsky, MichalLund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Barnkardiologi,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Children cardiology,Lund University Research Groups,Skåne University Hospital(Swepub:lu)mi1050od (författare)
  • Strait, JamesMerck Sharp & Dohme, Switzerland (författare)
  • de Graeff, PieterMedicines Evaluation Board, Utrecht (författare)
  • Stockbridge, NormanUnited States Food and Drug Administration (författare)
  • European Medicines Agency (EMA)United States Food and Drug Administration (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of the American Heart Association8:10, s. 1-102047-9980

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy